Summary
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced bowel cancer that is microsatellite stable.
Who can participate?
This study is for people with advanced colorectal cancer whose tumours are MSS/pMMR and whose cancer has continued to grow after standard treatments. These standard treatments may include chemotherapy drugs (like fluoropyrimidine, irinotecan, oxaliplatin, or Lonsurf), bevacizumab, and EGFR-targeted therapy (if eligible).
People who have previously received certain targeted therapies - for specific gene changes like BRAF V600E, HER2, KRAS G12C, RET, or NTRK - can also take part. However anyone who has taken fruquintinib or regorafenib before cannot join this study.
Study details
Participants will be randomly assigned (by chance) to one of two groups:
Group A - Experimental Treatment
- Atezolizumab (an immunotherapy) will be given intravenously (by IV) on Day 1 of each 28-day cycle
- DSP107 (a new investigational therapy) given by IV on Days 1, 8 and 15
- Infusions may get shorter over time if well tolerated
Group B - Comparison Treatment
- Fruquintinib, an approved oral cancer medicine
- Taken once daily for 21 days, followed by 7 days off, in each 28-day cycle
- Participants will keep a dosing diary
Each person's time in the study will be different depending on how well they tolerate treatment and whether their cancer grows. The study includes screening (up to 28 days), treatment (up to 24 treatment cycles), and safety follow-up (about 90 days after the last dose).